{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:49Z","timestamp":1787003629356,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tobacco use is the single largest cause of preventable death worldwide, but none of the established treatments aimed at smoking cessation work for a majority of smokers. As such, there is an urgent need for interventions capable of reliably treating nicotine addiction. The use of classic psychedelics has been associated with lower odds of many forms of substance dependence. Here we tested whether lifetime use of classic psychedelics (tryptamine, lysergamide, and phenethylamine) is associated with lower odds of current nicotine dependence. We tested these associations in a sample of 214,505 adult participants in the National Survey on Drug Use and Health (2015\u20132019) using multivariable logistic regression models. Lifetime psilocybin use was associated with reduced odds of odds of current nicotine dependence (aOR 0.87\u20130.93). Lifetime use of peyote and mescaline also conferred reduced odds of multiple subdomains of a main nicotine dependence measure (Nicotine Dependence Syndrome Scale [NDSS]) (aOR 0.79\u20130.91). Conversely, lifetime use of LSD was associated with increased odds of nicotine dependence (aOR 1.17\u20131.24). Psilocybin, mescaline, and peyote use are associated with lowered odds of nicotine dependence. Experimental studies are needed to establish whether these associations are causal. These results make the case for further research into the efficacy of both tryptamine and phenethylamine psychedelics in promoting smoking cessation.<\/jats:p>","DOI":"10.1038\/s41598-022-14809-3","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T14:03:01Z","timestamp":1655906581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Associations between classic psychedelics and nicotine dependence in a nationally representative sample"],"prefix":"10.1038","volume":"12","author":[{"given":"Grant","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Nock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"14809_CR1","volume-title":"WHO Report on the Global Tobacco Epidemic 2021: Addressing New and Emerging Products","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. WHO Report on the Global Tobacco Epidemic 2021: Addressing New and Emerging Products (World Health Organization, 2021)."},{"key":"14809_CR2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6552a1","author":"S Babb","year":"2017","unstructured":"Babb, S. Quitting smoking among adults: United States, 2000\u20132015. MMWR Morb. Mortal Wkly. Rep. https:\/\/doi.org\/10.15585\/mmwr.mm6552a1 (2017).","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"14809_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.15585\/mmwr.mm6845a2","volume":"68","author":"MR Creamer","year":"2019","unstructured":"Creamer, M. R. et al. Tobacco product use and cessation indicators among adults: United States, 2018. MMWR Morb. Mortal Wkly. Rep. 68, 1013\u20131019 (2019).","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"14809_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jama.2013.283787","volume":"311","author":"K Cahill","year":"2014","unstructured":"Cahill, K., Stevens, S. & Lancaster, T. Pharmacological treatments for smoking cessation. JAMA 311, 193\u2013194 (2014).","journal-title":"JAMA"},{"key":"14809_CR5","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/eurheartj\/ehn552","volume":"30","author":"S Mottillo","year":"2009","unstructured":"Mottillo, S. et al. Behavioural interventions for smoking cessation: A meta-analysis of randomized controlled trials. Eur. Heart J. 30, 718\u2013730 (2009).","journal-title":"Eur. Heart J."},{"key":"14809_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187, 268\u2013283 (2006).","journal-title":"Psychopharmacology"},{"key":"14809_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/02791072.2017.1312643","volume":"49","author":"MM Nour","year":"2017","unstructured":"Nour, M. M., Evans, L. & Carhart-Harris, R. Psychedelics, Personality and Political Perspectives. J Psychoactive Drugs 49, 182\u2013191 (2017).","journal-title":"J Psychoactive Drugs"},{"key":"14809_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1037\/gpr0000102","volume":"21","author":"DB Yaden","year":"2017","unstructured":"Yaden, D. B., Haidt, J., Hood, R. W. Jr., Vago, D. R. & Newberg, A. B. The varieties of self-transcendent experience. Rev. Gen. Psychol. 21, 143\u2013160 (2017).","journal-title":"Rev. Gen. Psychol."},{"key":"14809_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/09540261.2018.1474185","volume":"30","author":"PS Hendricks","year":"2018","unstructured":"Hendricks, P. S. Awe: A putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int. Rev. Psychiatry 30, 331\u2013342 (2018).","journal-title":"Int. Rev. Psychiatry"},{"key":"14809_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson, M. W., Hendricks, P. S., Barrett, F. S. & Griffiths, R. R. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Phamacol. Ther. 197, 83\u2013102 (2019).","journal-title":"Phamacol. Ther."},{"key":"14809_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/0269881117691453","volume":"31","author":"VD Pisano","year":"2017","unstructured":"Pisano, V. D. et al. The association of psychedelic use and opioid use disorders among illicit users in the United States. J. Psychopharmacol. 31, 606\u2013613 (2017).","journal-title":"J. Psychopharmacol."},{"key":"14809_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","volume":"10","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu, A. et al. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Front. Psychiatry 10, 955 (2019).","journal-title":"Front. Psychiatry"},{"key":"14809_CR13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881119845793","volume":"33","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu, A. et al. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J. Psychopharmacol. 33, 1088\u20131101 (2019).","journal-title":"J. Psychopharmacol."},{"key":"14809_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","volume":"4","author":"G Agin-Liebes","year":"2021","unstructured":"Agin-Liebes, G. et al. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol. Transl. Sci. 4, 543\u2013552 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"14809_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28, 983\u2013992 (2014).","journal-title":"J. Psychopharmacol."},{"key":"14809_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson, M. W., Garcia-Romeu, A. & Griffiths, R. R. Long-term follow-up of psilocybin-facilitated smoking cessation. Am. J. Drug. Alcohol Abuse 43, 55\u201360 (2017a).","journal-title":"Am. J. Drug. Alcohol Abuse"},{"key":"14809_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/0269881116684335","volume":"31","author":"MW Johnson","year":"2017","unstructured":"Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. & Griffiths, R. R. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J. Psychopharmacol. 31, 841\u2013850 (2017b).","journal-title":"J. Psychopharmacol."},{"key":"14809_CR18","volume-title":"Survey: Analysis of complex survey samples","author":"T Lumley","year":"2020","unstructured":"Lumley, T. Survey: Analysis of complex survey samples (Springer, 2020)."},{"key":"14809_CR19","volume-title":"lmtest: Testing Linear Regression Models","author":"T Hothorn","year":"2022","unstructured":"Hothorn, T. et al. lmtest: Testing Linear Regression Models (Springer, 2022)."},{"key":"14809_CR20","unstructured":"Johns Hopkins Medicine Newsroom. Johns Hopkins Medicine Receives first federal grant for psychedelic treatment research in 50 years. in Johns Hopkins Medicine Newsroom. (2021). https:\/\/www.hopkinsmedicine.org\/news\/newsroom\/news-releases\/johns-hopkins-medicine-receives-first-federal-grant-for-psychedelic-treatment-research-in-50-years. Accessed 9 Nov 2021."},{"key":"14809_CR21","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","volume":"12","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: A population-based survey study. Sci. Rep. 12, 2574 (2022).","journal-title":"Sci. Rep."},{"key":"14809_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/02698811211058923","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. MDMA\/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J. Psychopharmacol. 36, 46\u201356 (2022).","journal-title":"J. Psychopharmacol."},{"key":"14809_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","volume":"10","author":"JJ Fuentes","year":"2020","unstructured":"Fuentes, J. J., Fonseca, F., Elices, M., Farr\u00e9, M. & Torrens, M. Therapeutic use of LSD in psychiatry: A systematic review of randomized-controlled clinical trials. Front. Psychiatry 10, 943 (2020).","journal-title":"Front. Psychiatry"},{"key":"14809_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson, M. W., Richards, W. A. & Griffiths, R. R. Human hallucinogen research: Guidelines for safety. J. Psychopharmacol. 22, 603\u2013620 (2008).","journal-title":"J. Psychopharmacol."},{"key":"14809_CR25","volume-title":"Basic Econometrics","author":"DN Gujarati","year":"2003","unstructured":"Gujarati, D. N. Basic Econometrics 4th edn. (McGraw Hill, 2003).","edition":"4"},{"key":"14809_CR26","volume-title":"Applied Statistics and Probability for Engineers","author":"DC Montgomery","year":"2010","unstructured":"Montgomery, D. C. Applied Statistics and Probability for Engineers 5th edn. (Wiley, 2010).","edition":"5"},{"key":"14809_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris, R. L. & Friston, K. J. REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacol. Rev. 71, 316\u2013344 (2019).","journal-title":"Pharmacol. Rev."},{"key":"14809_CR28","doi-asserted-by":"publisher","first-page":"117906951880050","DOI":"10.1177\/1179069518800508","volume":"12","author":"DE Olson","year":"2018","unstructured":"Olson, D. E. Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. J. Exp. Neurosci. 12, 1179069518800508 (2018).","journal-title":"J. Exp. Neurosci."},{"key":"14809_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118143","volume":"10","author":"F Palhano-Fontes","year":"2015","unstructured":"Palhano-Fontes, F. et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS ONE 10, e0118143 (2015).","journal-title":"PLoS ONE"},{"key":"14809_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/dta.1376","volume":"4","author":"MP Bogenschutz","year":"2012","unstructured":"Bogenschutz, M. P. & Pommy, J. M. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Test. Anal. 4, 543\u2013555 (2012).","journal-title":"Drug Test. Anal."},{"key":"14809_CR31","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.neuropharm.2013.06.030","volume":"76","author":"KA Cunningham","year":"2014","unstructured":"Cunningham, K. A. & Anastasio, N. C. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology 76, 460\u2013478 (2014).","journal-title":"Neuropharmacology"},{"key":"14809_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/pr.114.009514","volume":"67","author":"LL Howell","year":"2015","unstructured":"Howell, L. L. & Cunningham, K. A. Serotonin 5-HT2 receptor interactions with dopamine function: Implications for therapeutics in cocaine use disorder. Pharmacol. Rev. 67, 176\u2013197 (2015).","journal-title":"Pharmacol. Rev."},{"key":"14809_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/B978-0-12-385506-0.00010-7","volume":"98","author":"Y Sari","year":"2011","unstructured":"Sari, Y., Johnson, V. R. & Weedman, J. M. Role of the serotonergic system in alcohol dependence: From animal models to clinics. Prog. Mol. Biol. Transl. Sci. 98, 401\u2013443 (2011).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"14809_CR34","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/ijms21051873","volume":"21","author":"C Bombardi","year":"2020","unstructured":"Bombardi, C. et al. Acute and chronic nicotine exposures differentially affect central serotonin 2A receptor function: Focus on the lateral habenula. Int. J. Mol. Sci. 21, 1873 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"14809_CR35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1021\/acschemneuro.5b00025","volume":"6","author":"GA Higgins","year":"2015","unstructured":"Higgins, G. A. & Fletcher, P. J. Therapeutic potential of 5-HT2C receptor agonists for addictive disorders. ACS Chem. Neurosci. 6, 1071\u20131088 (2015).","journal-title":"ACS Chem. Neurosci."},{"key":"14809_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2015","unstructured":"Garcia-Romeu, A., Griffiths, R. R. & Johnson, M. W. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr. Drug. Abuse Rev. 7, 157\u2013164 (2015).","journal-title":"Curr. Drug. Abuse Rev."},{"key":"14809_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1874473711666180612075954","volume":"11","author":"L Beraldo","year":"2019","unstructured":"Beraldo, L. et al. Spirituality, religiosity and addiction recovery: Current perspectives. Curr. Drug Res. Rev. 11, 26\u201332 (2019).","journal-title":"Curr. Drug Res. Rev."},{"key":"14809_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/10550490600754325","volume":"15","author":"M Galanter","year":"2006","unstructured":"Galanter, M. Spirituality and addiction: A research and clinical perspective. Am. J. Addict. 15, 286\u2013292 (2006).","journal-title":"Am. J. Addict."},{"key":"14809_CR39","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s10943-019-00876-w","volume":"58","author":"BJ Grim","year":"2019","unstructured":"Grim, B. J. & Grim, M. E. Belief, behavior, and belonging: how faith is indispensable in preventing and recovering from substance abuse. J. Relig. Health 58, 1713\u20131750 (2019).","journal-title":"J. Relig. Health"},{"key":"14809_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.15288\/jsad.2013.74.152","volume":"74","author":"RK McHugh","year":"2013","unstructured":"McHugh, R. K., Kaufman, J. S., Frost, K. H., Fitzmaurice, G. M. & Weiss, R. D. Positive affect and stress reactivity in alcohol-dependent outpatients. J. Stud. Alcohol Drugs 74, 152\u2013157 (2013).","journal-title":"J. Stud. Alcohol Drugs"},{"key":"14809_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/00952990.2016.1249283","volume":"44","author":"CE Wilcox","year":"2018","unstructured":"Wilcox, C. E. & Tonigan, J. S. Changes in depression mediate the effects of AA attendance on alcohol use outcomes. Am. J. Drug. Alcohol Abuse 44, 103\u2013112 (2018).","journal-title":"Am. J. Drug. Alcohol Abuse"},{"key":"14809_CR42","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean, K. A., Johnson, M. W. & Griffiths, R. R. Mystical experiences occasioned by the Hallucinogen psilocybin lead to increases in the personality domain of openness. J. Psychopharmacol. 25, 1453\u20131461 (2011).","journal-title":"J. Psychopharmacol."},{"key":"14809_CR43","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1038\/s41598-021-84746-0","volume":"11","author":"B Weiss","year":"2021","unstructured":"Weiss, B., Miller, J. D., Carter, N. T. & Keith Campbell, W. Examining changes in personality following shamanic ceremonial use of ayahuasca. Sci. Rep. 11, 6653 (2021).","journal-title":"Sci. Rep."},{"key":"14809_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.addbeh.2018.03.007","volume":"82","author":"N Zilberman","year":"2018","unstructured":"Zilberman, N., Yadid, G., Efrati, Y., Neumark, Y. & Rassovsky, Y. Personality profiles of substance and behavioral addictions. Addict Behav 82, 174\u2013181 (2018).","journal-title":"Addict Behav"},{"key":"14809_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz, M. P. et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J. Psychopharmacol. 29, 289\u2013299 (2015).","journal-title":"J. Psychopharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14809-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:52:38Z","timestamp":1669337558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14809-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14809"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14809-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"14 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10578"}}